Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 13/20 | 0.77 |
| ▸ | CTSK | P43235 | 12/20 | 0.77 |
| ▸ | CTSB | P07858 | 4/20 | 0.77 |
| ▸ | CTSL | P07711 | 2/20 | 0.77 |
| ▸ | AKT1 | P31749 | 1/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | ACE | P12821 | 1/20 | 0.60 |
| ▸ | REN | P00797 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21137542 | 0.93 | CTSS (0.68) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL8815536 | 0.93 | CTSS (0.74) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL8815530 | 0.93 | CTSS (0.74) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL18766807 | 0.92 | CTSS (0.67) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL18766806 | 0.92 | CTSS (0.67) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL10040933 | 0.91 | CTSS (0.79) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL21010315 | 0.91 | CTSS (0.79) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL2440946 | 0.91 | CTSS (0.79) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL23529664 | 0.90 | CTSS (0.64) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL14485901 | 0.90 | CTSS (0.74) | CTSSCTSKCTSBCTSLAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-11263783-A | — | — | None | — | — | JP | disclosed |
| US-8268789-B2 | PAR-2 antagonists | KOWA COMPANY, LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-8268789-B2 | PAR-2 antagonists | KOWA COMPANY, LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-8268789-B2 | PAR-2 antagonists | KOWA COMPANY, LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| EP-1806141-B1 | PAR-2 ANTAGONISTS | KOWA CO (JP) | 2010-12-01 | — | — | EP | disclosed |
| EP-1806141-B1 | PAR-2 ANTAGONISTS | KOWA CO (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-20090012006-A1 | Par-2 Antagonists | KOWA COMPANY, LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20090012006-A1 | Par-2 Antagonists | KOWA COMPANY, LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20090012006-A1 | Par-2 Antagonists | KOWA COMPANY, LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1806141-A1 | PAR-2 ANTAGONISTS | Kowa Company, Ltd. (JP) | 2007-07-11 | — | — | EP | disclosed |
| JP-H11263783-A | EPOXYSUCCINAMIC ACID DERIVATIVE | TAISHO PHARMACEUT CO LTD | 1999-09-28 | — | — | JP | disclosed |
| EP-0753003-B1 | AZIRIDINE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-06-16 | — | — | EP | disclosed |
| US-5668128-A | INHIBITORS OF THIOL PROTEASE, PROPHYLAXIS AND TREATMENT OF BONE DISEASES, OSTEOPOROSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-09-16 | — | — | US | disclosed |
| EP-0753003-A1 | AZIRIDINE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1997-01-15 | — | — | EP | disclosed |
| WO-1995028416-A1 | AZIRIDINE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012006-A1 | Par-2 Antagonists | F2RL1, F2R, F2RL3 | CTSS 308/4885CTSK 513/4885CTSB 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.